Cancer vaccine shows early promise in gastric cancer clinical trial
MELBOURNE Australia 07 February 2018: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company is pleased to announce its HER-Vaxx cancer vaccine (IMU-131) is showing early promise in patients with metastatic gastric cancer and feedback from clinicians running the study has been positive.
Strong immune responses measured in the first patients dosed
Dose escalation recommended after no safety, toxicity or tolerability issues
Clinical data will guide recommended dose for planned Phase 2 study
For further information please download PDF attached:
Download this document